| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T444 |
0-23 |
Sentence |
denotes |
In 2018, Groutas et al. |
| T445 |
24-156 |
Sentence |
denotes |
151 disclosed a novel class of dual MERS‐CoV and SARS‐CoV‐1 Mpro inhibitors that contain a P3‐piperidine moiety (58–59; Figure 17). |
| T446 |
157-383 |
Sentence |
denotes |
These inhibitors were derived from the dipeptidic‐aldehyde bisulfite adduct 57 (GC376), which was clinically studied as a protease inhibitor for its efficacy against CoVs such as the feline infectious peritonitis virus (FIPV). |
| T447 |
384-517 |
Sentence |
denotes |
Compounds 58 and 59 showed potent antiviral activity toward MERS‐CoV in cell‐based bioassays (EC50, 0.5 µM for 58 and 0.8 µM for 59). |
| T448 |
518-653 |
Sentence |
denotes |
SAR studies revealed that the piperidine moiety engaged in favorable hydrophobic interactions at the S3 and S4 pockets of the protease. |
